← Browse by Condition
Medical Condition
invasive breast carcinoma
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2
ClinicalMetric tracks all active clinical trials for invasive breast carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — invasive breast carcinoma Clinical Trials
How many clinical trials are currently recruiting for invasive breast carcinoma?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for invasive breast carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for invasive breast carcinoma?
invasive breast carcinoma research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a invasive breast carcinoma clinical trial?
Eligibility criteria for invasive breast carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07191717 Phase 2
Recruiting
Enrollment
42 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
NCT04959474
Recruiting
Enrollment
80 pts
Location
United States
Sponsor
Thomas Jefferson University
NCT05786664
Recruiting
Enrollment
1,300 pts
Location
United States
Sponsor
University of Southern Califor...
NCT03606967 Phase 2
Recruiting
Enrollment
86 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT05059444
Recruiting
Enrollment
2,020 pts
Location
United States, Franc...
Sponsor
Guardant Health, Inc.
NCT06744465
Recruiting
Enrollment
15 pts
Location
United States
Sponsor
Indiana University
Related Conditions
anatomic stage i breast cancer ajcc v8 (2) anatomic stage ii breast cancer ajcc v8 (2) anatomic stage iii breast cancer ajcc v8 (2) localized estrogen receptor positive breast carcinoma (1) localized human epidermal growth factor receptor her2 negative breast carcinoma (1) anatomic stage 0 breast cancer ajcc v8 (1) anatomic stage 1 breast cancer ajcc v8 (1) anatomic stage 2 breast cancer ajcc v8 (1) anatomic stage 3 breast cancer ajcc v8 (1) breast ductal carcinoma in situ (1) triple negative breast carcinoma (1) anatomic stage iv breast cancer ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology